If you know someone with early-stage Parkinson's disease, they may be eligible for this clinical research study.
Clinical research studies (also called clinical trials) are critical for identifying new ways of treating medical conditions and diseases. All medications must be tested in clinical research studies before they can be approved and prescribed to patients. The Orchestra Study is a clinical research study for people with early-stage Parkinson’s disease. The aim of the study is to see whether the investigational medication known as UCB0599 can slow Parkinson’s disease progression.
Parkinson’s disease is a progressive (gets worse over time) nervous system disorder that not only affects movement, but also a wide range of other functions, including mood, mental function and various bodily functions. Both the pace of progression and the range of symptoms are highly variable from person to person.
There are an estimated 7 to 10 million individuals with Parkinson’s disease worldwide. The age of onset is approximately 60 years, although this varies between individuals. In people living with Parkinson’s disease, symptoms appear over time and slowly get worse. The most common symptoms in typical Parkinson’s disease are: slowness of movement, difficult-to-control shaking, and stiffness of muscles. These types of symptoms related to movement are called motor symptoms. There are also non-motor symptoms such as: loss of smell, depression, constipation, pain, and sleep disorder.
Some of these may occur early in the disease. The presence of these non-motor symptoms in particular can be highly variable from person to person and can also change over time in an individual. The disease develops due to a reduction in a chemical messenger in the brain called dopamine, which is involved in the control of movement. Brain cells containing dopamine die due to a build-up of protein clumps inside them known as Lewy bodies. These clumps form due to misfolding of a protein known as alpha-synuclein. By developing medications that prevent the clumping of Lewy bodies in the brain, it may be possible to slow down the worsening of Parkinson’s disease.